Talking Biotech with Dr. Kevin Folta Colabra
-
- Science
Talking Biotech is a weekly podcast that uncovers the stories, ideas and research of people at the frontier of biology and engineering.
Each episode explores how science and technology will transform agriculture, protect the environment, and feed 10 billion people by 2050.
Interviews are led by Dr. Kevin Folta, a professor of molecular biology and genomics.
-
Standardizing Therapeutic Protein Production in Plants - Jim Wilson
Where many therapeutic compounds are raised in bacteria or fungi, plants sometimes offer many advantages as bioreactors. Capital and production costs are lower, and products may be edible instead of injectable. The problem tends to be standardization, and conditions that ensure that the desired proteins are produced This episode features Jim Wilson from Zea Biologics, where cleanrooms, precise regulation of all aspects of the plant growth environment, and massive data collection, allow for the production of biological compounds to treat everything from hemophilia to influenza. The compounds are bio-encapsulated, a patented process that allows oral delivery instead of injection. Using precision "pharming" drugs and be produced at a lower cost in less time, and the products are temperature stable, allowing wider distribution at lower cost, with a lower carbon footprint.
www.zeabio.com -
Canadian Rules for Gene Editing - Jennifer Hubert
Canada has a unique approach to plant genetic improvement that follows the product, not the process. In other words, if there is potential risk from any genetic manipulation technique, from polyploidization to transgenic to gene edits, Canadian regulators assess the relative risk in the final product. But what does the regulatory climate look like going forward as gene editing becomes more routine? Today's podcast is a conversation with Jennifer Hubert, Executive Director of Biotechnology at Crop Life Canada.
-
Overcoming CAR-T Cell Bottlenecks - Dr. Andy Scharenberg
Immunotherapy is weaponizing the body's immune system against cancer or other disease. One of the most promising approaches is CAR-T cell therapy, yet as this technology has been implemented, it's limitations have been identified. Dr. Andy Scharenberg described the current drawbacks of CAR-T cells and how his company, Umoja, is re-engineering CAR-T cells in vivo to create more effective therapies, including approaches that can address solid tumors. Co-hosted by Donald Coon.
www.umoja-biopharma.com -
The FDA Regulatory Ecosystem- Expert Panel Discusses the Process
How do new drug applications move forward to approval? Four experts discuss the partnership between the FDA, the drug developer, and the data needed to move a product forward. It is a surprising discussion that reveals the depth of the FDA process. Joined by Dr. Debra Webster, Dr. Julia Marre, Dr. Michael Matthews and Dr. Jonathan Helfgott.
-
The Psychology of Risk - Dr. Felicia Wu
We live in amazing times of technological advance, but how are the real benefits of new tech lost to an inflated sense of risk? Dr. Felicia Wu from Michigan State University shares her expertise in describing the psychological basis of risk and applying it to questions like glyphosate and aspartame.
-
Restoring the Forest with GE American Chestnut - Dr. Andy Newhouse and Erik Carlson
This is an update on the American Chestnut Restoration Project, as discussed previously on the podcast. The American Chestnut dominated the forests of Appalachia until an imported fungus destroyed the entire range. Efforts to restore the chestnut and its ecology have employed a biotechnology approach, integrating a gene from wheat that limits the mechanism the fungus uses to attack the tree. Dr. Andy Newhouse and Erik Carlson join the podcast to discuss progress in the project.